PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FDA grants ODD to Nexcella’s multiple myeloma treatment

The drug is currently being assessed in a phase 1b/2a clinical trial.

Nexcella has announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to NXC-201 for the treatment of multiple myeloma. The drug is currently being assessed in the phase 1b/2a NEXICART-1 clinical trial.

The ODD qualifies the drug for seven years of US market exclusivity once it is approved, tax credits for qualified clinical testing and a waiver of the Prescription Drug User Fee (currently nearing $3m for a new drug). The FDA grants this status to drugs and biologics intended for safe and effective treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the US.

Ilya Rachman, executive chairman of Nexcella, commented: “We are pleased to receive FDA’s ODD in multiple myeloma for NXC-201, the only clinical-stage BCMA-targeted CAR T-cell therapy with no neurotoxicity observed in over 50 patients dosed to date.

“We are thrilled to potentially expand therapeutic options for multiple myeloma patients while eliminating the most feared adverse effect of this therapeutic class, neurotoxicity.”

Gabriel Morris, president of Nexcella, added: “ODD for NXC-201 represents a substantial value-creating step along our path to unlocking planned wide adoption of CAR T technology by transitioning it to an outpatient domain.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026